The Endocrinology Advisor had an article on the FDA’s decision to place a Black Box warning on canagliflozin drug labels to include prominent boxed warnings describing the risk to patients.

“Data from 2 large clinical trials have confirmed that treatment of type 2 diabetes with canagliflozin (Invokana®, Invokamet®, and Invokamet XR®; Janssen Pharmaceuticals, Inc.) may lead to an increased risk of leg and foot amputations, according to a US Food and Drug Administration (FDA) Drug Safety Communication.”

Comments are closed.

Post Navigation